Nab-Paclitaxel and Radiation for Unresectable Pancreatic Cancer

This clinical trial aims to find better treatment methods for individuals with pancreatic cancer that cannot be surgically removed or is on the borderline of being removable. The study looks to improve how well local treatments work in controlling the cancer and boosting survival rates by using a combination of a chemotherapy drug called nab-paclitaxel and increased doses of radiation therapy. The trial is significant because it explores using nab-paclitaxel’s unique properties to enhance the effectiveness of radiation, offering hope for improved management of this challenging cancer type. Participants in the study will receive nab-paclitaxel alongside radiation therapy to see how the combined treatment affects the cancer. In the beginning, the dose of nab-paclitaxel will be increased while radiation remains at a standard level to find the maximum tolerated dose. Later, the treatment will include the addition of a drug called paricalcitol. The study uses advanced radiation technologies like IMRT or protons to target the cancer effectively while protecting nearby healthy tissues. Patients may also receive standard chemotherapy before or after this combined treatment. The study closely monitors for any adverse effects to ensure safety and gather insights on the treatment’s impact.